Mesirow Financial Investment Management Inc. boosted its stake in Omeros Co. (NASDAQ:OMER) by 35.6% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 18,808 shares of the biopharmaceutical company’s stock after purchasing an additional 4,940 shares during the quarter. Mesirow Financial Investment Management Inc.’s holdings in Omeros were worth $365,000 as of its most recent SEC filing.
Other hedge funds also recently made changes to their positions in the company. Teachers Advisors LLC lifted its stake in Omeros by 66.2% in the 2nd quarter. Teachers Advisors LLC now owns 113,509 shares of the biopharmaceutical company’s stock worth $2,259,000 after purchasing an additional 45,224 shares in the last quarter. Ingalls & Snyder LLC lifted its stake in Omeros by 0.3% in the 3rd quarter. Ingalls & Snyder LLC now owns 5,161,035 shares of the biopharmaceutical company’s stock worth $111,582,000 after purchasing an additional 17,746 shares in the last quarter. Alliancebernstein L.P. lifted its stake in Omeros by 40.1% in the 2nd quarter. Alliancebernstein L.P. now owns 61,500 shares of the biopharmaceutical company’s stock worth $1,224,000 after purchasing an additional 17,600 shares in the last quarter. State Street Corp lifted its stake in Omeros by 7.3% in the 2nd quarter. State Street Corp now owns 987,057 shares of the biopharmaceutical company’s stock worth $19,652,000 after purchasing an additional 66,827 shares in the last quarter. Finally, EAM Investors LLC lifted its stake in Omeros by 30.4% in the 3rd quarter. EAM Investors LLC now owns 202,025 shares of the biopharmaceutical company’s stock worth $4,368,000 after purchasing an additional 47,146 shares in the last quarter. Institutional investors and hedge funds own 49.71% of the company’s stock.
Shares of Omeros Co. (NASDAQ OMER) opened at $19.60 on Tuesday. The company has a current ratio of 4.77, a quick ratio of 4.74 and a debt-to-equity ratio of 8.99. The stock has a market cap of $940.87, a PE ratio of -15.31 and a beta of 3.56. Omeros Co. has a 1 year low of $8.71 and a 1 year high of $27.09.
Omeros (NASDAQ:OMER) last announced its earnings results on Thursday, November 9th. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.34) by $0.18. The business had revenue of $21.66 million for the quarter, compared to analysts’ expectations of $17.82 million. The firm’s quarterly revenue was up 91.9% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.34) earnings per share. sell-side analysts anticipate that Omeros Co. will post -0.98 earnings per share for the current fiscal year.
Several brokerages have commented on OMER. HC Wainwright set a $30.00 price target on shares of Omeros and gave the stock a “buy” rating in a research note on Thursday, December 14th. Maxim Group set a $24.00 target price on shares of Omeros and gave the company a “buy” rating in a research report on Wednesday, January 3rd. Cowen cut shares of Omeros from an “outperform” rating to a “market perform” rating in a research report on Thursday, November 2nd. Finally, Zacks Investment Research cut shares of Omeros from a “hold” rating to a “sell” rating in a research report on Thursday, November 9th. Five research analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $34.14.
Omeros Company Profile
Omeros Corporation is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing small-molecule and protein therapeutics for large-market, as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. Its marketed drug product, Omidria (phenylephrine and ketorolac injection), is used during cataract surgery or intraocular lens (IOL) replacement.
Want to see what other hedge funds are holding OMER? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Omeros Co. (NASDAQ:OMER).
Receive News & Ratings for Omeros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros and related companies with MarketBeat.com's FREE daily email newsletter.